Comparative Risk of Hepatitis B Virus Reactivation in Patients Receiving Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitors for Liver Cancer.

ABSTRACT:

Background

Current and past hepatitis B virus (HBV) infection remains the leading cause of liver cancer in endemic areas.

Aim

To examine the risk of HBV reactivation (HBVr) in patients receiving immune checkpoint inhibitors (ICI) for liver cancer.

Methods

Patients with current or past HBV infection receiving systemic treatments for liver cancer from March 2015 to March 2023 were identified using a territory-wide electronic database in Hong Kong. The primary outcome was HBVr in ICI compared to tyrosine kinase inhibitor (TKI) use, defined according to the American Association for the Study of Liver Diseases criteria. The secondary outcome was HBVr in different types of ICI.

Results

One thousand five hundred and ninty-six patients with current or past HBV infectio

SUBMITTER: Yiu DC 

PROVIDER: S-EPMC12807337 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature